Kyntra Bio Receives Nasdaq Notice of Non-Compliance with Continued Listing Requirements

On April 2, 2026, Kyntra Bio, Inc. received a deficiency letter from the Nasdaq Listing Qualifications Staff indicating that the company no longer complies with Nasdaq Global Select Market Listing Rule 5450(b)(3)(A). Specifically, the company failed to meet the requirement of $50 million in total assets and total revenue for the most recently completed fiscal year. This non-compliance is attributed to the revenue of FibroGen International being classified as held for sale in discontinued operations for 2024 and 2025. Additionally, the company does not currently meet alternative listing standards related to shareholders’ equity or market value of listed securities. The notice does not result in an immediate delisting. Kyntra Bio has 45 days (until May 18, 2026) to submit a plan to regain compliance. If Nasdaq accepts the plan, the company may be granted an extension of up to 180 days (until September 29, 2026) to demonstrate compliance. The company is also considering a potential transfer of its securities to the Nasdaq Capital Market.